hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06280118, orgStudyIdInfo id: EFCPR008, briefTitle: The Effect of Fatigue on CPR, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-04-20, primaryCompletionDateStruct date: 2023-06-20, completionDateStruct date: 2023-10-25, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Artvin Coruh University, class: OTHER, descriptionModule briefSummary: Background: This study, in contrast to the previous studies, generated a scenario of fatigue in an earthquake scenario and aimed to measure the effect of fatigue on the quality of cardiopulmonary resuscitation (CPR) performed by paramedics in a debris course.Methods: The study was designed as a randomized controlled trial. The sample, consisting of 84 paramedic students, was randomly assigned as 42 control and 42 experimental groups. Fatigue was created in the participants by rehearsing the process of removing and transporting earthquake victims from the rubble through the prepared track. A personal information form and a CPR measurement form were used to obtain the data. The simulator was used to evaluate the accuracy of CPR. The collected data were analysed with the statistical program., conditionsModule conditions: Resuscitation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized controlled trial, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 84, type: ACTUAL, armsInterventionsModule interventions name: Fatigue, outcomesModule primaryOutcomes measure: Correct number of ventilations, primaryOutcomes measure: Correct number of compression, secondaryOutcomes measure: CPR duration, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 24 Years, stdAges: ADULT, contactsLocationsModule locations facility: Resuscitation simulation laboratory of Artvin Çoruh University Health Services Vocational School, city: Artvin, zip: 08000, country: Turkey, geoPoint lat: 41.18161, lon: 41.82172, hasResults: False
protocolSection identificationModule nctId: NCT06280105, orgStudyIdInfo id: 2023_148_01, briefTitle: A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-31, primaryCompletionDateStruct date: 2026-03-31, completionDateStruct date: 2027-03-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Meng Chao Hepatobiliary Hospital of Fujian Medical University, class: OTHER, descriptionModule briefSummary: To evaluate the efficacy and safety of cadonilimab combined with Regorafenib in patients with hepatocellular carcinoma who failed camrelizumab plus apatinib., conditionsModule conditions: Hepatocellular Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Cadonilimab+regorafenib, outcomesModule primaryOutcomes measure: objective response rate (ORR) per RECIST1.1, secondaryOutcomes measure: Progression-free survival（PFS）, secondaryOutcomes measure: Overall survival（OS）, secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Occurence of AE and SAE, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mengchao Hepatobiliary Hospital, Fujian Medical University, city: Fuzhou, state: Fujian, country: China, geoPoint lat: 26.06139, lon: 119.30611, hasResults: False
protocolSection identificationModule nctId: NCT06280092, orgStudyIdInfo id: 23-009133, briefTitle: Allogenic Adipose-derived Mesenchymal Stem Cells(AMSCs) for Epilepsy During Deep Brain Stimulation(DBS) Surgery, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Sanjeet S. Grewal, class: OTHER, descriptionModule briefSummary: This study is a non-randomized, open label, phase 1 clinical trial to evaluate the fesibility and safety of intrathalamic delivery of MSCs during standard of care DBS surgery for epilepsy.Subjects will be screened at our outpatient clinic and interested qualified subjects will be consented and offered participation in this trial. Once consent has been obtained, patients will undergo a standard preoperative evaluation which includes baseline laboratory values and a high-definition MRI. Patients will then undergo a stereotactic procedure for bilateral thalamic implantation of DBS leads through the ClearPoint® system. After the thalamic target for DBS is identified, cells will be infused directly into the anterior nucleus of the thalamus previous to lead implantation.Patients will be followed in the outpatient setting for up to a year after therapy application.Surgical, clinical, and radiographic data will be obtained during these visits, conditionsModule conditions: Epilepsy, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: A single dose of 5x10\^6 AMSCs will be resuspended in 1ml of LRS and infused via intraparenchymal at the time of DBS surgery, primaryPurpose: OTHER, maskingInfo masking: NONE, maskingDescription: This is an unmasked study, enrollmentInfo count: 5, type: ESTIMATED, armsInterventionsModule interventions name: AMSCs, outcomesModule primaryOutcomes measure: Primary Objective, primaryOutcomes measure: Secondary Objective, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06280053, orgStudyIdInfo id: 103-3024A3, briefTitle: HealiAid in the Treatment of Different Wounds, statusModule overallStatus: COMPLETED, startDateStruct date: 2016-03-02, primaryCompletionDateStruct date: 2018-04-11, completionDateStruct date: 2018-10-26, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Maxigen Biotech Inc., class: INDUSTRY, descriptionModule briefSummary: The goal of this open-label, post-market clinical follow-up study is to demonstrate the safety and effectiveness of HealiAid Collagen Wound Dressing in patients classified into different types of wounds: venous ulcers, bedsores, diabetic foot wounds and burn wounds.The main questions it aims to answer are:1. The wound healing which was defined as the percentage of area change.2. The duration of wound healing.3. The granulation tissue growth of the wound.4. The wound exudate.5. Safety Indicators of which incidences after treatment.HealiAid will be applied to eligible subjects who will later be followed up for 12 weeks., conditionsModule conditions: Venous Ulcers, conditions: Bedsores, conditions: Diabetic Foot Wound, conditions: Burn Wound, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: The patients' wound conditions were divided into four types: venous ulcers, bedsores, diabetic foot wounds and burn wounds., primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 18, type: ACTUAL, armsInterventionsModule interventions name: HealiAid Collagen Wound Dressing, outcomesModule primaryOutcomes measure: Wound Healing, secondaryOutcomes measure: Wound Healing, secondaryOutcomes measure: Duration of Wound Healing, secondaryOutcomes measure: Granulation Tissue Growth, secondaryOutcomes measure: Wound Exudate, secondaryOutcomes measure: Incidence of Safety Events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06280040, orgStudyIdInfo id: UM Longitudinal 1942/2022, briefTitle: Longitudinal Follow-Up of Patients Treated With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal Melanoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-23, primaryCompletionDateStruct date: 2025-06-30, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Medical University of Vienna, class: OTHER, descriptionModule briefSummary: The purpose of this study is to evaluate the incidence and severity of retinopathy and opticopathy one year after treatment with hypofractionated stereotactic photon radiotherapy due to uveal melanoma. Patients will be imaged before radiation, as well as 3, 6, 9 and 12 months after radiation using sonography funds photography, optical coherence tomography angiography, oximeter and microperimetry., conditionsModule conditions: Uveal Melanoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Clinical examination and multimodal ocular imaging, outcomesModule primaryOutcomes measure: Incidence and Severity of Retinopathy, secondaryOutcomes measure: Incidence and Severity of Opticopathy, secondaryOutcomes measure: Functional Outcome, secondaryOutcomes measure: Incidence and Severity of Retinopathy and Opticopathy in oximeter, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Ophthalmology and Optometry, Medical University Vienna, status: RECRUITING, city: Vienna, zip: 1090, country: Austria, contacts name: Judith Kreminger, MD, role: CONTACT, phone: 0043 1 40400 48470, email: judith.kreminger@meduniwien.ac.at, contacts name: Reinhard Told, MD, PhD, Priv.-Doz., role: CONTACT, phone: 0043 1 40400 48470, email: reinhard.told@meduniwien.ac.at, contacts name: Adrian Reumueller, MD, Priv.-Doz, role: SUB_INVESTIGATOR, contacts name: Roman Dunavoelgyi, MD, Assoc.-Prof., role: SUB_INVESTIGATOR, geoPoint lat: 48.20849, lon: 16.37208, hasResults: False
protocolSection identificationModule nctId: NCT06280014, orgStudyIdInfo id: YYU-09/15.12.2021, briefTitle: Evaluation of the Effects of Mefenamic Acid and Dexketoprofen on Postoperative Wisdom Dental Surgery, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-01-20, primaryCompletionDateStruct date: 2022-02-20, completionDateStruct date: 2023-09-25, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Yuzuncu Yıl University, class: OTHER, descriptionModule briefSummary: This study was administered to 22 female and 8 male patients. Patients with impacted wisdom teeth on both sides of the mandible were selected. After impacted tooth extraction, the patient used mefenamic acid on one side and dexketoprofen on the other side for postoperative pain relief. The effects of these two materials on patient comfort were investigated., conditionsModule conditions: Tooth, Impacted, conditions: Tooth Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ACTUAL, armsInterventionsModule interventions name: Surgery of impacted mandibular wisdom teeth, interventions name: Surgery of impacted mandibular wisdom teeth, outcomesModule primaryOutcomes measure: Mouth opening measurements, primaryOutcomes measure: Facial edema, primaryOutcomes measure: Visual Analog Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Serap Keskin Tunc, city: Van, zip: 65100, country: Turkey, geoPoint lat: 38.49457, lon: 43.38323, hasResults: False
protocolSection identificationModule nctId: NCT06280001, orgStudyIdInfo id: 2023YFC2308802-04, briefTitle: A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum of HIV/AIDS Complicated With Infection, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2026-11, completionDateStruct date: 2026-11, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Zhejiang University, class: OTHER, collaborators name: Beijing Ditan Hospital, collaborators name: Beijing YouAn Hospital, collaborators name: Huashan Hospital, collaborators name: Qilu Hospital of Shandong University, descriptionModule briefSummary: The goal of this observational study is to determine the incidence and spectrum of opportunistic infections among Chinese HIV/AIDS patients at this stage, to find intervention targets, to construct an early warning prediction model, and to give an individualized program with integrated immune function to obtain salvage opportunities for patients.The main questions it aims to answer are:* Describe the populations and characteristics of pathogenic microorganisms involved in HIV co-infection, map the spatial and temporal changes in the infection system of pathogenic microorganisms, and evaluate their impact on disease regression.* Explore the mechanism of interaction between pathogenic microorganisms and host autoimmune deficiencies.* Discover early warning and predictive markers and immunological indicators of pathogenic microorganisms, and explore new technologies and programs to reduce the mortality rate of infection., conditionsModule conditions: Acquired Immunodeficiency Syndrome, conditions: HIV Infections, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 500, type: ESTIMATED, outcomesModule primaryOutcomes measure: Secondary infections in patients with HIV/AIDS at 4 weeks, primaryOutcomes measure: quick SEPSIS RELATED ORGAN FAILURE ASSESSMENT(qSOFA) at 4 weeks, secondaryOutcomes measure: Survival rate, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06279975, orgStudyIdInfo id: Req-2023-01275; am23Sutter2, briefTitle: Pupillometric Evaluation in Patients Declared Brain Dead - a Prospective Quality Control Study, acronym: INSPECT, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-18, primaryCompletionDateStruct date: 2029-12, completionDateStruct date: 2030-12, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: University Hospital, Basel, Switzerland, class: OTHER, descriptionModule briefSummary: The aim of the study is to verify the reliability of the current purely clinical examination of the pupils (without the support of a pupillometer) in the context of clinically suspected brain death, compared to the results of a non-invasive, automated, and highly precise monocular pupillometric examination., conditionsModule conditions: Brain Death, conditions: Adults, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: non-invasive device-supported, automated pupillometry, outcomesModule primaryOutcomes measure: Reliability of clinical examination of pupils in patients with suspected brain death, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Intensive care unit at the University Hospital Basel, status: RECRUITING, city: Basel, state: Basel-Stadt, zip: 4031, country: Switzerland, contacts name: Raoul Sutter, Prof., role: CONTACT, phone: +41 61 328 7928, email: raoul.sutter@usb.ch, contacts name: Raoul Sutter, Prof., role: PRINCIPAL_INVESTIGATOR, contacts name: Pascale Grzonka, MD, role: SUB_INVESTIGATOR, geoPoint lat: 47.55839, lon: 7.57327, locations facility: University Hospital Basel, status: RECRUITING, city: Basel, country: Switzerland, contacts name: Raoul Sutter, Prof., role: CONTACT, email: raoul.sutter@usb.ch, contacts name: Pascale Grzonka, MD, role: CONTACT, email: PascaleSusanne.Grzonka@usb.ch, geoPoint lat: 47.55839, lon: 7.57327, hasResults: False
protocolSection identificationModule nctId: NCT06279962, orgStudyIdInfo id: 2000034620, briefTitle: Survey Experiment to Estimate Level of Mental Illness Stigma Based on Condition and Gender, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-06-15, primaryCompletionDateStruct date: 2023-09-15, completionDateStruct date: 2023-09-15, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Yale University, class: OTHER, collaborators name: Empower Through Health, descriptionModule briefSummary: This study aims to measure levels of mental illness stigma based on condition and gender of the participants and individual portrayed with mental illness., conditionsModule conditions: Mental Illness, conditions: Stigma, Social, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 379, type: ACTUAL, armsInterventionsModule interventions name: Survey questionnaire, outcomesModule primaryOutcomes measure: Level of acceptance for the individual depicted in the vignette as measured by PERSONAL ACCEPTANCE SCALE, primaryOutcomes measure: Level of acceptance for the individual depicted in the vignette as measured by BROAD ACCEPTANCE SCALE, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Empowerment to Heal - Uganda, city: Iganga, country: Uganda, geoPoint lat: 0.60917, lon: 33.46861, hasResults: False
protocolSection identificationModule nctId: NCT06279949, orgStudyIdInfo id: 2000036999, secondaryIdInfos id: 1K01MH136929-01, type: OTHER, domain: NIMH *ID not yet added, briefTitle: Confidential Care and Adolescent HIV Testing, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2026-04, primaryCompletionDateStruct date: 2027-10, completionDateStruct date: 2027-10, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Yale University, class: OTHER, collaborators name: National Institute of Mental Health (NIMH), descriptionModule briefSummary: The purpose of this study is to assess the feasibility and acceptability of structural intervention components to increase adolescent HIV testing uptake by improving the implementation of confidential care as standard practice in pediatric primary care., conditionsModule conditions: Hiv, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: FACTORIAL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 4, type: ESTIMATED, armsInterventionsModule interventions name: Provider training, interventions name: Clinic protocols, outcomesModule primaryOutcomes measure: Feasibility, defined as the extent to which structural intervention components to improve confidential care implementation can be successfully carried out in pediatric primary care settings, primaryOutcomes measure: Acceptability, defined as the perception among pediatric primary care clinic leadership and providers that structural intervention components to improve confidential care implementation are agreeable or satisfactory, primaryOutcomes measure: Change in HIV testing uptake, secondaryOutcomes measure: Reach, defined as the number of adolescent patients who receive confidential care, secondaryOutcomes measure: Adoption, defined as the proportion of pediatric primary care providers who have time alone with and/or provide confidentiality assurances to adolescent patients, secondaryOutcomes measure: Implementation, defined as pediatric primary care provider fidelity to confidential care provision, secondaryOutcomes measure: Maintenance, defined as the extent to which confidential care is provided and adolescent patients are screened for, accept, and receive results of HIV testing 6-months post-intervention, eligibilityModule sex: ALL, minimumAge: 13 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06279923, orgStudyIdInfo id: TXB2023023, briefTitle: CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2027-02-01, completionDateStruct date: 2027-02-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Zhejiang University, class: OTHER, collaborators name: Shanghai YaKe Biotechnology Ltd., descriptionModule briefSummary: Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for Autoimmune Diseases., conditionsModule conditions: Autoimmune Diseases, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: CD19-BAFF Targeted CAR T-cells, outcomesModule primaryOutcomes measure: Dose-limiting toxicity (DLT), primaryOutcomes measure: Incidence of treatment-emergent adverse events (TEAEs), secondaryOutcomes measure: Multiple Myeloma (MM), Overall response rate (ORR), secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Duration of remission,DOR, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The first affiliated hospital of medical college of zhejiang university, status: RECRUITING, city: Hangzhou, state: Zhejiang, zip: 310000, country: China, contacts name: He Huang, MD, role: CONTACT, phone: 86-13605714822, email: hehuangyu@126.com, contacts name: Yongxian Hu, MD, role: CONTACT, phone: +8615957162012, email: huyongxian2000@aliyun.com, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False